Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Elisabetta Patorno, Dr.P.H., M.D.

Co-Author

This page shows the publications co-authored by Elisabetta Patorno and Deborah Wexler.
Connection Strength

1.848
  1. Three Sides to the Story: Adherence Trajectories During the First Year of SGLT2 Inhibitor Therapy Among Medicare Beneficiaries. Diabetes Care. 2022 03 01; 45(3):604-613.
    View in: PubMed
    Score: 0.240
  2. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Ann Intern Med. 2022 01; 175(1):W4-W5.
    View in: PubMed
    Score: 0.238
  3. Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes Obes Metab. 2022 03; 24(3):442-454.
    View in: PubMed
    Score: 0.236
  4. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes. Am J Kidney Dis. 2022 06; 79(6):858-867.e1.
    View in: PubMed
    Score: 0.235
  5. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. JAMA Netw Open. 2021 10 01; 4(10):e2130762.
    View in: PubMed
    Score: 0.234
  6. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Ann Intern Med. 2021 11; 174(11):1528-1541.
    View in: PubMed
    Score: 0.233
  7. Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults. Diabetes Care. 2021 03; 44(3):826-835.
    View in: PubMed
    Score: 0.223
  8. Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018. Diabetes Care. 2020 04; 43(4):921-924.
    View in: PubMed
    Score: 0.208
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.